A variety of prognostic tools have been developed over the years for this purpose, utilizing clinical variables (e.g., tumor number and size) [62,63], laboratory values (e.g., AFP, γ-glutamyl transferase levels) [64,65], molecular biomarkers (e.g., Ki67, microRNA-1268a, cochlin) [66,67,68], immunologic parameters (e.g., CD8+ cell infiltration and programmed death-ligand 1 expression) [69], and circulating tumor cells [70]. The gene discussed is CD8A; the disease is neoplasm.